Trial Profile
The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Monotherapy Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Dulaglutide (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AWARD-CHN1
- Sponsors Eli Lilly and Company
- 16 Jun 2020 Results of post-hoc analysis presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 11 Jun 2019 Post hoc analysis results from AWARD-CHN1 and AWARD-CHN2 studies were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
- 22 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.